Multiple sclerosis - natalizumab (TA127)
Natalizumab is recommended as a possible treatment for people with rapidly evolving severe relapsing-remitting multiple sclerosis.
Healthcare professionals should not stop prescribing natalizumab for people with other types of multiple sclerosis who were already taking it when the guidance was issued. These people should be able to carry on taking natalizumab until they and their doctor decide that it is the right time to stop.
- TA127 Multiple sclerosis - natalizumab: review decision - July 2013
- TA127 Multiple sclerosis - natalizumab: review poposal - May 2013
- Review Decision - December 2010
- Review proposal - October 2010
- NICE recommends natalizumab for the treatment of multiple sclerosis
- TA127 Multiple sclerosis - natalizumab: distribution list
This page was last updated: 09 July 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA127 Natalizumab fel triniaeth i oedolion sydd â sglerosis ymledol gweithredol iawn sy'n ailwaelu-dychwelyd: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.